{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:47:39Z","timestamp":1790632059600,"version":"4.1.0"},"reference-count":140,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS110784"],"award-info":[{"award-number":["R01NS110784"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The term \u201cprion disease\u201d encompasses a group of neurodegenerative diseases affecting both humans and animals. Currently, there is no effective therapy and all forms of prion disease are invariably fatal. Because of (a) the outbreak of bovine spongiform encephalopathy in cattle and variant Creutzfeldt\u2013Jakob disease in humans; (b) the heated debate about the prion hypothesis; and (c) the availability of a natural prion disease in rodents, the understanding of the pathogenic process in prion disease is much more advanced compared to that of other neurodegenerative disorders, which inspired many attempts to develop therapeutic strategies against these fatal diseases. In this review, we focus on immunotherapy against prion disease. We explain our rationale for immunotherapy as a plausible therapeutic choice, review previous trials using either active or passive immunization, and discuss potential strategies for overcoming the hurdles in developing a successful immunotherapy. We propose that immunotherapy is a plausible and practical therapeutic strategy and advocate more studies in this area to develop effective measures to control and treat these devastating disorders.<\/jats:p>","DOI":"10.3390\/pathogens9030216","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T09:27:41Z","timestamp":1584437261000},"page":"216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immunotherapy against Prion Disease"],"prefix":"10.3390","volume":"9","author":[{"given":"Yue","family":"Ma","sequence":"first","affiliation":[{"name":"Center for Neurodegenerative Science, Van Andel Institute, 333 Bostwick Avenue N.E., Grand Rapids, MI 49503, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Ma","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Science, Van Andel Institute, 333 Bostwick Avenue N.E., Grand Rapids, MI 49503, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.6801762","article-title":"Novel proteinaceous infectious particles cause scrapie","volume":"216","author":"Prusiner","year":"1982","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/B978-0-12-802395-2.00028-6","article-title":"Prion diseases","volume":"145","author":"Ironside","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bpa.12696","article-title":"Animal prion diseases: The risks to human health","volume":"29","author":"Houston","year":"2019","journal-title":"Brain Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.pmbts.2017.06.018","article-title":"Cell biology of prion protein","volume":"150","author":"Sarnataro","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1212\/WNL.42.1.149","article-title":"Nearly ubiquitous tissue distribution of the scrapie agent precursor protein","volume":"42","author":"Bendheim","year":"1992","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1099\/vir.0.79889-0","article-title":"Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice","volume":"85","author":"Lloyd","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1099\/0022-1317-83-3-695","article-title":"Strain characterization of natural sheep scrapie and comparison with BSE","volume":"83","author":"Bruce","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Igel-Egalon, A., Beringue, V., Rezaei, H., and Sibille, P. (2018). Prion strains and transmission barrier phenomena. Pathogens, 7.","DOI":"10.3390\/pathogens7010005"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bartz, J.C. (2016). Prion strain diversity. Cold Spring Harb. Perspect. Med., 6.","DOI":"10.1101\/cshperspect.a024349"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1138718","article-title":"A general model of prion strains and their pathogenicity","volume":"318","author":"Collinge","year":"2007","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1187107","article-title":"Prion strain mutation determined by prion protein conformational compatibility and primary structure","volume":"328","author":"Angers","year":"2010","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Giles, K., Olson, S.H., and Prusiner, S.B. (2017). Developing therapeutics for PrP prion diseases. Cold Spring Harb. Perspect. Med., 7.","DOI":"10.1101\/cshperspect.a023747"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pharmtox-010617-052745","article-title":"Toward therapy of human prion diseases","volume":"58","author":"Aguzzi","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrneurol.2012.258","article-title":"Immunotherapy in prion disease","volume":"9","author":"Roettger","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00018-009-0031-5","article-title":"Aptamers against prion proteins and prions","volume":"66","author":"Gilch","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/nar\/gks1132","article-title":"Anti-Prion activity of an RNA aptamer and its structural basis","volume":"41","author":"Mashima","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/nri3553","article-title":"The immunobiology of prion diseases","volume":"13","author":"Aguzzi","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Raymond, G.J., Zhao, H.T., Race, B., Raymond, L.D., Williams, K., Swayze, E.E., Graffam, S., Le, J., Caron, T., and Stathopoulos, J. (2019). Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight, 5.","DOI":"10.1172\/jci.insight.131175"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/jnc.14877","article-title":"Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression","volume":"152","author":"Hannaoui","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/19336896.2019.1670928","article-title":"Combining autophagy stimulators and cellulose ethers for therapy against prion disease","volume":"13","author":"Abdulrahman","year":"2019","journal-title":"Prion"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Teruya, K., Oguma, A., Nishizawa, K., Kawata, M., Sakasegawa, Y., Kamitakahara, H., and Doh-Ura, K. (2016). A single subcutaneous injection of cellulose ethers administered long before infection confers sustained protection against prion diseases in rodents. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1006045"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature01457","article-title":"Monoclonal antibodies inhibit prion replication and delay the development of prion disease","volume":"422","author":"White","year":"2003","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dyer, C. (2018). British man with CJD gets experimental treatment in world first. BMJ, 363.","DOI":"10.1136\/bmj.k4608"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rosenberg, R.N., and Lambracht-Washington, D. (2019). Active immunotherapy to prevent Alzheimer disease-a DNA amyloid \u03b2 1\u201342 trimer vaccine. JAMA Neurol.","DOI":"10.1001\/jamaneurol.2019.4182"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Loureiro, J.C., Pais, M.V., Stella, F., Radanovic, M., Teixeira, A.L., Forlenza, O.V., and de Souza, L.C. (2020). Passive antiamyloid immunotherapy for Alzheimer\u2019s disease. Curr. Opin. Psychiatry.","DOI":"10.1097\/YCO.0000000000000587"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.1183748","article-title":"Generating a prion with bacterially expressed recombinant prion protein","volume":"327","author":"Wang","year":"2010","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E1938","DOI":"10.1073\/pnas.1206999109","article-title":"Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions","volume":"109","author":"Deleault","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.biochem.78.082907.145410","article-title":"Getting a grip on prions: Oligomers, amyloids, and pathological membrane interactions","volume":"78","author":"Caughey","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Reimann, R.R., Sonati, T., Hornemann, S., Herrmann, U.S., Arand, M., Hawke, S., and Aguzzi, A. (2016). Differential toxicity of antibodies to the prion protein. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005401"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature11058","article-title":"Sustained translational repression by eIF2\u03b2-P mediates prion neurodegeneration","volume":"485","author":"Moreno","year":"2012","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Moreno, J.A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J.M., Ortori, C.A., Willis, A.E., Fischer, P.M., and Barrett, D.A. (2013). Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3006767"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.116.235556","article-title":"Optimization of aryl amides that extend survival in prion-infected mice","volume":"358","author":"Giles","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E4160","DOI":"10.1073\/pnas.1317164110","article-title":"Drug resistance confounding prion therapeutics","volume":"110","author":"Berry","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/infdis\/jiu656","article-title":"Use of a 2-aminothiazole to treat chronic wasting disease in transgenic mice","volume":"212","author":"Berry","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1006\/jmbi.1999.2831","article-title":"Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein","volume":"289","author":"Wopfner","year":"1999","journal-title":"J. Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sevillano, A.M., Fernandez-Borges, N., Younas, N., Wang, F., Elezgarai, R.S., Bravo, S., Vazquez-Fernandez, E., Rosa, I., Erana, H., and Gil, D. (2018). Recombinant PrPSc shares structural features with brain-derived PrPSc: Insights from limited proteolysis. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006797"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2015.03.008","article-title":"Proteinase K and the structure of PrPSc: The good, the bad and the ugly","volume":"207","author":"Silva","year":"2015","journal-title":"Virus Res."},{"key":"ref_44","first-page":"323","article-title":"Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies","volume":"386","author":"Lee","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/ja407527p","article-title":"Probing the N-terminal \u03b2-sheet conversion in the crystal structure of the human prion protein bound to a nanobody","volume":"136","author":"Abskharon","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Osterholm, M.T., Anderson, C.J., Zabel, M.D., Scheftel, J.M., Moore, K.A., and Appleby, B.S. (2019). Chronic wasting disease in cervids: implications for prion transmission to humans and other animal species. mBio, 10.","DOI":"10.1128\/mBio.01091-19"},{"key":"ref_47","first-page":"123","article-title":"Chronic wasting disease in cervids: Prevalence, impact and management strategies","volume":"10","author":"Rivera","year":"2019","journal-title":"Vet. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13567-016-0375-4","article-title":"First case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer","volume":"47","author":"Benestad","year":"2016","journal-title":"Vet. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1292\/jvms.64.855","article-title":"A case of chronic wasting disease in an elk imported to Korea from Canada","volume":"64","author":"Sohn","year":"2002","journal-title":"J. Vet. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1292\/jvms.67.753","article-title":"Additional cases of chronic wasting disease in imported deer in Korea","volume":"67","author":"Kim","year":"2005","journal-title":"J. Vet. Med. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1354\/vp.42-5-530","article-title":"Chronic wasting disease","volume":"42","author":"Williams","year":"2005","journal-title":"Vet. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/19336896.2015.1118603","article-title":"Cross-species transmission of CWD prions","volume":"10","author":"Kurt","year":"2016","journal-title":"Prion"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hannaoui, S., Schatzl, H.M., and Gilch, S. (2017). Chronic wasting disease: Emerging prions and their potential risk. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006619"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13794","DOI":"10.1128\/JVI.79.21.13794-13796.2005","article-title":"Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus)","volume":"79","author":"Marsh","year":"2005","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3201\/eid1509.090253","article-title":"Susceptibilities of nonhuman primates to chronic wasting disease","volume":"15","author":"Race","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.1183218","article-title":"Darwinian evolution of prions in cell culture","volume":"327","author":"Li","year":"2010","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev-animal-022114-111001","article-title":"Chronic wasting disease of cervids: Current knowledge and future perspectives","volume":"3","author":"Haley","year":"2015","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Mathiason, C.K., Hays, S.A., Powers, J., Hayes-Klug, J., Langenberg, J., Dahmes, S.J., Osborn, D.A., Miller, K.V., Warren, R.J., and Mason, G.L. (2009). Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely by environmental exposure. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005916"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2014.11.035","article-title":"Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease","volume":"33","author":"Goni","year":"2015","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mabbott, N.A. (2017). How do PrP(Sc) prions spread between host species, and within hosts?. Pathogens, 6.","DOI":"10.3390\/pathogens6040060"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14670","DOI":"10.1073\/pnas.0404772101","article-title":"Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection","volume":"101","author":"Polymenidou","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.4049\/jimmunol.175.10.6443","article-title":"The murine B cell repertoire is severely selected against endogenous cellular prion protein","volume":"175","author":"Gregoire","year":"2005","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/1521-4141(200108)31:8<2338::AID-IMMU2338>3.0.CO;2-V","article-title":"Modulation of proteinase-K resistant prion protein by prion peptide immunization","volume":"31","author":"Souan","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1742-4658.2007.05721.x","article-title":"Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells","volume":"274","author":"Handisurya","year":"2007","journal-title":"FEBS J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1128\/JVI.79.7.4033-4042.2005","article-title":"Circumventing tolerance to the prion protein (PrP): Vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP","volume":"79","author":"Nikles","year":"2005","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.4049\/jimmunol.172.9.5168","article-title":"Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice","volume":"172","author":"Rosset","year":"2004","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1099\/vir.0.013417-0","article-title":"Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie","volume":"91","author":"Bachy","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10538","DOI":"10.1038\/s41598-017-11235-8","article-title":"Immunization of cervidized transgenic mice with multimeric deer prion protein induces self-antibodies that antagonize chronic wasting disease infectivity In Vitro","volume":"7","author":"Abdelaziz","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"19812","DOI":"10.1074\/jbc.RA118.004810","article-title":"Recombinant prion protein vaccination of transgenic elk PrP mice and reindeer overcomes self-tolerance and protects mice against chronic wasting disease","volume":"293","author":"Abdelaziz","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.vaccine.2006.09.078","article-title":"Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion","volume":"25","author":"Ishibashi","year":"2007","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/j.vaccine.2004.11.067","article-title":"Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters","volume":"23","author":"Magri","year":"2005","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-5728(02)00316-8","article-title":"Induction of antibodies against murine full-length prion protein in wild-type mice","volume":"132","author":"Koller","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(03)00907-8","article-title":"Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent","volume":"350","author":"Schwarz","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1099\/vir.0.005041-0","article-title":"Unswitched immunoglobulin M response prolongs mouse survival in prion disease","volume":"90","author":"Tayebi","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"18524","DOI":"10.1074\/jbc.M210723200","article-title":"Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells","volume":"278","author":"Gilch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1016\/j.vaccine.2011.10.017","article-title":"Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice","volume":"29","author":"Ishibashi","year":"2011","journal-title":"Vaccine"},{"key":"ref_77","first-page":"523","article-title":"Immune responses in wild-type mice against prion proteins induced using a DNA prime-protein boost strategy","volume":"24","author":"Han","year":"2011","journal-title":"Biomed. Env. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/dna.2009.0940","article-title":"Electrotransfer of cDNA coding for a heterologous prion protein generates autoantibodies against native murine prion protein in wild-type mice","volume":"29","author":"Alexandrenne","year":"2010","journal-title":"DNA Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.neuroscience.2005.02.031","article-title":"Mucosal vaccination delays or prevents prion infection via an oral route","volume":"133","author":"Goni","year":"2005","journal-title":"Neuroscience"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuroscience.2008.02.051","article-title":"High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice","volume":"153","author":"Goni","year":"2008","journal-title":"Neuroscience"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cellimm.2010.03.018","article-title":"Anti-PrP antibodies detected at terminal stage of prion-affected mouse","volume":"263","author":"Sassa","year":"2010","journal-title":"Cell. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.vaccine.2014.01.027","article-title":"Development of a multivalent, PrP(Sc)-specific prion vaccine through rational optimization of three disease-specific epitopes","volume":"32","author":"Marciniuk","year":"2014","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/pri.27962","article-title":"Safety, specificity and immunogenicity of a PrP(Sc)-specific prion vaccine based on the YYR disease specific epitope","volume":"8","author":"Taschuk","year":"2014","journal-title":"Prion"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/19336896.2017.1367083","article-title":"Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease","volume":"11","author":"Taschuk","year":"2017","journal-title":"Prion"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1016\/j.vaccine.2018.10.057","article-title":"Accelerated onset of chronic wasting disease in elk (Cervus canadensis) vaccinated with a PrP(Sc)-specific vaccine and housed in a prion contaminated environment","volume":"36","author":"Wood","year":"2018","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0002-9440(10)64151-X","article-title":"Immunization delays the onset of prion disease in mice","volume":"161","author":"Sigurdsson","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.179.5.2797","article-title":"Polylactide-Coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses","volume":"179","author":"Heit","year":"2007","journal-title":"J. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Xanthopoulos, K., Lagoudaki, R., Kontana, A., Kyratsous, C., Panagiotidis, C., Grigoriadis, N., Yiangou, M., and Sklaviadis, T. (2013). Immunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanism. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059143"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.vaccine.2005.12.051","article-title":"Intranasal immunization of Balb\/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy","volume":"24","author":"Bade","year":"2006","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.181.1.768","article-title":"Contribution of antibody and T cell-specific responses to the progression of 139A-scrapie in C57BL\/6 mice immunized with prion protein peptides","volume":"181","author":"Sacquin","year":"2008","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neulet.2007.10.015","article-title":"Anti-Prion activity generated by a novel vaccine formulation","volume":"429","author":"Pilon","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Rosset, M.B., Sacquin, A., Lecollinet, S., Chaigneau, T., Adam, M., Crespeau, F., and Eloit, M. (2009). Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004917"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9970","DOI":"10.1128\/JVI.01210-06","article-title":"DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge","volume":"80","author":"Brun","year":"2006","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.vetmic.2007.03.032","article-title":"Immunisation strategies against prion diseases: Prime-Boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie","volume":"123","author":"Nitschke","year":"2007","journal-title":"Vet. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.vaccine.2009.10.134","article-title":"Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses","volume":"28","author":"Hedlin","year":"2010","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9295","DOI":"10.1073\/pnas.151242598","article-title":"Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody","volume":"98","author":"Enari","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35089090","article-title":"Antibodies inhibit prion propagation and clear cell cultures of prion infectivity","volume":"412","author":"Peretz","year":"2001","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1471-4159.2004.02356.x","article-title":"Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation","volume":"89","author":"Perrier","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"11247","DOI":"10.1074\/jbc.M407006200","article-title":"Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells","volume":"280","author":"Feraudet","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/j.1460-9568.2006.04805.x","article-title":"Clearance and prevention of prion infection in cell culture by anti-PrP antibodies","volume":"23","author":"Pankiewicz","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3940(02)01192-8","article-title":"Anti-Prion antibodies for prophylaxis following prion exposure in mice","volume":"336","author":"Sigurdsson","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nbd.2009.01.013","article-title":"Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1\/22L and in the lymphoreticular system In Vivo","volume":"34","author":"Sadowski","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.83578-0","article-title":"Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice","volume":"89","author":"Song","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.1063093","article-title":"Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies","volume":"294","author":"Heppner","year":"2001","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300387","article-title":"CNS delivery of vectored prion-specific single-chain antibodies delays disease onset","volume":"16","author":"Wuertzer","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1128\/JVI.02467-10","article-title":"Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions","volume":"85","author":"Petsch","year":"2011","journal-title":"J. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4161\/pri.20197","article-title":"Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice","volume":"6","author":"Moda","year":"2012","journal-title":"Prion"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14760584.2015.965691","article-title":"Prospects for safe and effective vaccines against prion diseases","volume":"14","author":"Mabbott","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1126\/science.1094273","article-title":"Cross-Linking cellular prion protein triggers neuronal apoptosis In Vivo","volume":"303","author":"Solforosi","year":"2004","journal-title":"Science"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12402","article-title":"The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein","volume":"501","author":"Sonati","year":"2013","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4161\/pri.1.3.4870","article-title":"Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice","volume":"1","author":"Kremmer","year":"2007","journal-title":"Prion"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.1215579","article-title":"PrP antibodies do not trigger mouse hippocampal neuron apoptosis","volume":"335","author":"Klohn","year":"2012","journal-title":"Science"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Herrmann, U.S., Sonati, T., Falsig, J., Reimann, R.R., Dametto, P., O\u2019Connor, T., Li, B., Lau, A., Hornemann, S., and Sorce, S. (2015). Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004662"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Senatore, A., Frontzek, K., Emmenegger, M., Chincisan, A., Losa, M., Reimann, R., Horny, G., Guo, J., Fels, S., and Sorce, S. (2020). Protective anti-prion antibodies in human immunoglobulin. bioRxiv, in press.","DOI":"10.1101\/2020.02.05.933721"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41598-018-36700-w","article-title":"Structural features distinguishing infectious Ex Vivo mammalian prions from non-infectious fibrillar assemblies generated in vitro","volume":"9","author":"Terry","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Wang, F., Wang, X., Orru, C.D., Groveman, B.R., Surewicz, K., Abskharon, R., Imamura, M., Yokoyama, T., Kim, Y.S., and Vander Stel, K.J. (2017). Self-Propagating, protease-resistant, recombinant prion protein conformers with or without in vivo pathogenicity. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006491"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"18494","DOI":"10.1074\/jbc.RA118.005622","article-title":"Structural attributes of mammalian prion infectivity: Insights from studies with synthetic prions","volume":"293","author":"Li","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nm987","article-title":"Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration","volume":"10","author":"Heikenwalder","year":"2004","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI200113155","article-title":"Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie","volume":"108","author":"Aucouturier","year":"2001","journal-title":"J. Clin. Invest."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"12","author":"Pulgar","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","article-title":"Viral vectors for therapy of neurologic diseases","volume":"120","author":"Choudhury","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","article-title":"Crossing the blood-brain barrier: Recent advances in drug delivery to the brain","volume":"31","author":"Patel","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-Brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/bs.pmbts.2017.06.009","article-title":"The Structure of the infectious prion protein and its propagation","volume":"150","author":"Requena","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Spagnolli, G., Rigoli, M., Orioli, S., Sevillano, A.M., Faccioli, P., Wille, H., Biasini, E., and Requena, J.R. (2019). Full atomistic model of prion structure and conversion. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007864"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/19336896.2019.1569450","article-title":"The prion 2018 round tables (I): The structure of PrP(Sc)","volume":"13","author":"Baskakov","year":"2019","journal-title":"Prion"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Vazquez-Fernandez, E., Vos, M.R., Afanasyev, P., Cebey, L., Sevillano, A.M., Vidal, E., Rosa, I., Renault, L., Ramos, A., and Peters, P.J. (2016). The structural architecture of an infectious mammalian prion using electron cryomicroscopy. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005835"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Jones, D.R., Taylor, W.A., Bate, C., David, M., and Tayebi, M. (2010). A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009804"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2014.05.001","article-title":"Potential candidate camelid antibodies for the treatment of protein-misfolding diseases","volume":"272","author":"David","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Abskharon, R., Wang, F., Wohlkonig, A., Ruan, J., Soror, S., Giachin, G., Pardon, E., Zou, W., Legname, G., and Ma, J. (2019). Structural evidence for the critical role of the prion protein hydrophobic region in forming an infectious prion. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1008139"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nature07761","article-title":"Cellular prion protein mediates impairment of synaptic plasticity by amyloid-\u03b2 oligomers","volume":"457","author":"Lauren","year":"2009","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/ncomms1341","article-title":"Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites","volume":"2","author":"Freir","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1523\/JNEUROSCI.3526-13.2014","article-title":"Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer\u2019s disease Abeta synaptotoxicity","volume":"34","author":"Klyubin","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.nbd.2016.03.001","article-title":"Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Abeta oligomers: Implications for novel therapeutic strategy in Alzheimer\u2019s disease","volume":"91","author":"Surewicz","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/nn.4648","article-title":"\u03b1-Synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B","volume":"20","author":"Ferreira","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"10050","DOI":"10.1038\/s41598-017-10236-x","article-title":"\u03b1-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication","volume":"7","author":"Aulic","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Corbett, G.T., Wang, Z., Hong, W., Colom-Cadena, M., Rose, J., Liao, M., Asfaw, A., Hall, T.C., Ding, L., and DeSousa, A. (2019). PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol., 503\u2013526.","DOI":"10.1007\/s00401-019-02114-9"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/3\/216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:06:54Z","timestamp":1760173614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/3\/216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":140,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["pathogens9030216"],"URL":"https:\/\/doi.org\/10.3390\/pathogens9030216","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,14]]}}}